![]() There is one small-molecule MCT inhibitor specific for MCT1 (AZD3965), which is being tested in a clinical trial for advanced adult diffuse large B-cell lymphoma and Burkitt lymphoma ( ). MCT inhibitors are not yet in clinical practice. Unfortunately, the efforts to develop pan-MCT- or MCT4-specific inhibitors have not been successful. Both in vitro and in vivo preclinical studies have shown that ablation of MCT1 or MCT4 can halt the proliferative capability of tumor cells, and MCT inhibition can be augmented with metformin and phenformin used widely in diabetes mellitus. MCT inhibitors have been proposed as good candidates for antitumor drugs since MCT expression has been reported in various human tumors, including, e.g., breast, colon, bladder, and prostate carcinomas, and gliomas. It is also well known that MCTs form metabolon systems, enhancing lactate transport, with different CA isozymes and even with noncatalytic CA-related proteins. ![]() ![]() Of the 14 isoforms, MCTs 1–4 have been extensively studied, because they can transport L-lactate and pyruvate across the plasma membrane. They are expressed in a wide variety of normal tissues and take part in key metabolic pathways. Monocarboxylate transporters (MCTs) are members of the solute carrier (SLC) family of proteins. ![]() Seppo Parkkila, in pH-Interfering Agents as Chemosensitizers in Cancer Therapy, 2021 Monocarboxylate transporters ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |